COSM (COSM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

COSM (COSM) Healthcare & Pipeline Overview

Cosmos Health Inc. is a vertically integrated pharmaceutical company that operates in the specialty and generic drug market, offering a range of products from pharmaceuticals to medical devices. With a small market capitalization and negative profitability, Cosmos Health aims to expand its proprietary product line and leverage its European distribution network.

What Is the Investment Thesis for COSM?

The investment thesis for Cosmos Health Inc. centers on its potential to leverage its vertically integrated structure and European distribution network to expand its market presence. Key to this thesis is the successful commercialization of its proprietary product line, which could drive revenue growth. However, the company's current financial standing, characterized by a small market capitalization of approximately $13 million and a negative profit margin of -29.3%, presents significant risks. Investors should monitor the company's ability to improve its gross margin, currently at 12.1%, and manage its high beta of 4.46, reflecting significant market volatility. The success of Cosmos Health hinges on its ability to execute its growth strategy and achieve profitability in a competitive market.

Based on FMP financials and quantitative analysis

COSM Key Highlights

Market Cap of $13.8M indicates a small capitalization company with potential for high growth but also higher risk.

• Profit Margin of -29.3% reflects current challenges in achieving profitability, requiring significant operational improvements.
• Gross Margin of 12.1% is relatively low, suggesting potential issues with cost of goods sold or pricing strategy.
• Beta of 4.46 indicates high volatility compared to the market, making it a riskier investment.
• Vertically integrated operations provide control over the supply chain, potentially leading to cost efficiencies and better quality control.

Who Are COSM's Competitors?

COSM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are COSM's Key Strengths?

Vertically integrated operations

• Distribution network in Europe
• Proprietary line of branded products
• E-commerce marketplace

What Are COSM's Weaknesses?

Small market capitalization

• Negative profit margin
• Low gross margin
• High beta indicating high volatility

What Could Drive COSM Stock Higher?

COSM catalyst: Launch of new proprietary pharmaceutical products aimed at specific therapeutic areas, expected in Q3 2026.

• Expansion of the e-commerce platform to increase direct-to-consumer sales and improve customer engagement.
• Strategic partnerships with European distributors to enhance market penetration and expand geographic reach.

What Are the Key Risks for COSM?

Listing risk — at $0.2532 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.

• Financial-distress signal — its Altman Z-Score of -2.92 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-96.5%) — the business is not currently generating profit on shareholder capital.
• Intense competition from larger pharmaceutical companies with greater resources and market share.
• Regulatory hurdles and compliance requirements that could delay product approvals and increase operational costs.
• Economic downturns affecting consumer spending on healthcare products and nutraceuticals.
• Fluctuations in currency exchange rates impacting revenue and profitability in European markets.

What Are the Growth Opportunities for COSM?

• Expansion of Proprietary Product Line: Cosmos Health has the opportunity to grow by expanding its line of branded and generic pharmaceuticals, nutraceuticals, and over-the-counter medications. Successfully developing and marketing new products in this space could drive revenue growth and improve profitability for Cosmos Health. This expansion hinges on effective R&D and marketing strategies.
• Leveraging European Distribution Network: With distribution centers in Greece and the United Kingdom, Cosmos Health can leverage its existing infrastructure to expand its market reach across Europe. The European pharmaceutical market is one of the largest in the world, offering substantial growth potential. By strengthening relationships with wholesale pharmaceutical distributors and independent retail pharmacies, Cosmos Health can increase its sales volume and market share. This requires strategic partnerships and efficient logistics management.
• E-commerce Marketplace Growth: Cosmos Health's e-commerce marketplace provides a direct-to-consumer channel that can drive revenue growth and improve brand visibility. The global e-commerce market is rapidly expanding, with healthcare products representing a growing segment. By enhancing its online platform, improving customer experience, and implementing targeted marketing campaigns, Cosmos Health can attract more customers and increase online sales. This strategy requires investments in technology and digital marketing.
• Strategic Acquisitions: Cosmos Health can pursue strategic acquisitions to expand its product portfolio, geographic reach, and market share. Acquiring complementary businesses or product lines can provide synergies and accelerate growth. For example, acquiring a company with a strong presence in a specific therapeutic area or geographic market could significantly enhance Cosmos Health's competitive position. However, successful acquisitions require careful due diligence and integration planning.
• Development of Medical Devices: Cosmos Health's involvement in medical devices presents a growth opportunity, particularly in specialized segments. The global medical device market is characterized by innovation and technological advancements. By focusing on developing and commercializing innovative medical devices, Cosmos Health can tap into a high-growth market segment. This requires investments in R&D, regulatory approvals, and strategic partnerships with healthcare providers.

What Are COSM's Competitive Advantages?

• Vertically integrated operations provide control over the supply chain.
• Distribution centers in Europe offer a strategic advantage in the European market.
• Proprietary line of branded products differentiates it from generic competitors.
• E-commerce marketplace provides a direct-to-consumer sales channel.

What Does COSM Do?

Cosmos Health Inc., established in 2009 and headquartered in Chicago, Illinois, operates as a vertically integrated pharmaceutical company. The company focuses on identifying, acquiring, developing, and commercializing a diverse range of healthcare products. These include branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, health care and baby products, and medical devices. Cosmos Health distributes these products through its established distribution channels and an e-commerce marketplace, catering to wholesale pharmaceutical distributors and independent retail pharmacies. With distribution centers strategically located in Greece and the United Kingdom, Cosmos Health maintains a warehousing facility to support its operations. The company's vertically integrated model allows it to manage various aspects of the supply chain, from product development to distribution, aiming to enhance efficiency and control. Cosmos Health's strategy involves expanding its proprietary product line and leveraging its European distribution network to drive growth and improve profitability in the competitive pharmaceutical market.

What Products and Services Does COSM Offer?

• Develop and commercialize branded and generic pharmaceuticals.
• Offer a range of nutraceutical products.
• Provide over-the-counter medications for various health conditions.
• Distribute health care and baby products.
• Offer medical devices through various channels.
• Operate an e-commerce marketplace for direct-to-consumer sales.
• Serve wholesale pharmaceutical distributors and independent retail pharmacies.

How Does COSM Make Money?

• Develop, acquire, and commercialize healthcare products.
• Distribute products through wholesale and retail channels.
• Operate an e-commerce marketplace for direct sales.
• Generate revenue from the sale of pharmaceuticals, nutraceuticals, and medical devices.

What Industry Does COSM Operate In?

Cosmos Health Inc. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and regulatory scrutiny. The global generic drug market is expected to continue growing, driven by increasing healthcare costs and the expiration of patents on branded drugs. Cosmos Health's focus on vertically integrated operations and its European distribution network positions it to potentially capitalize on these trends. However, it faces competition from larger, more established players with greater resources and market share. The company's ability to navigate regulatory landscapes and differentiate its product offerings will be critical for success.

Who Are COSM's Key Customers?

• Wholesale pharmaceutical distributors
• Independent retail pharmacies
• Individual consumers through e-commerce
• Healthcare providers

Company Profile

COSM operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Thessaloniki, GR. The company is led by CEO Grigorios Siokas. COSM has traded publicly since 2010.

COSM Financial Trajectory

COSM (COSM) reported $19.0M in revenue for Q2 FY2026, reflecting 5.9% growth compared to the prior quarter. The company recorded a net loss of $6.1M, with diluted EPS of $-0.10. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, COSM averaged $-0.17 in diluted EPS.

How COSM Is Valued

COSM carries a market capitalization of $13.8M, placing it in the micro-cap category.

Return on equity for COSM stands at -96.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -96.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations.

COSM's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.92 places it in the distress zone, a signal of elevated financial risk.

COSM has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 475.4% below estimates on average.

Over the past six months, COSM insiders filed 20 SEC Form 4 transactions — 7 sales and 13 purchases. On net that is roughly 2.5M shares acquired (about $1.5M) — insiders putting money in tends to read as conviction.

COSM Financials

COSM Latest News

COSM Analyst Consensus

COSM MoonshotScore

COSM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources